220 related articles for article (PubMed ID: 10541824)
1. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
Seitz U; Neumaier B; Glatting G; Kotzerke J; Bunjes D; Reske SN
Eur J Nucl Med; 1999 Oct; 26(10):1265-73. PubMed ID: 10541824
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
Kotzerke J; Glatting G; Seitz U; Rentschler M; Neumaier B; Bunjes D; Duncker C; Dohr D; Bergmann L; Reske SN
J Nucl Med; 2000 Mar; 41(3):531-7. PubMed ID: 10716329
[TBL] [Abstract][Full Text] [Related]
4. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy.
Uccelli L; Martini P; Pasquali M; Boschi A
Biomed Res Int; 2017; 2017():5923609. PubMed ID: 28951872
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
9. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Ringhoffer M; Blumstein N; Neumaier B; Glatting G; von Harsdorf S; Buchmann I; Wiesneth M; Kotzerke J; Zenz T; Buck AK; Schauwecker P; Stilgenbauer S; Döhner H; Reske SN; Bunjes D
Br J Haematol; 2005 Aug; 130(4):604-13. PubMed ID: 16098076
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
Buchmann I; Kull T; Glatting G; Bunjes D; Hale G; Kotzerke J; Rattat D; Dohner H; Reske SN
Eur J Nucl Med Mol Imaging; 2003 May; 30(5):667-73. PubMed ID: 12599012
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry with (188)Re-labelled monoclonal anti-CD66 antibodies. A simplified approach based on a single measurement 3 h p.i.
Glatting G; Kull T; Blumstein NM; Bunjes D; Neumaier B; Buck AK; Reske SN
Nuklearmedizin; 2006; 45(3):134-8. PubMed ID: 16710510
[TBL] [Abstract][Full Text] [Related]
12. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
Rajendran JG; Fisher DR; Gopal AK; Durack LD; Press OW; Eary JF
J Nucl Med; 2004 Jun; 45(6):1059-64. PubMed ID: 15181141
[TBL] [Abstract][Full Text] [Related]
13. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation.
Reske SN; Bunjes D; Buchmann I; Seitz U; Glatting G; Neumaier B; Kotzerke J; Buck A; Martin H; Döhner H; Bergmann L
Eur J Nucl Med; 2001 Jul; 28(7):807-15. PubMed ID: 11504076
[TBL] [Abstract][Full Text] [Related]
14. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
15. Rhenium-188: availability from the (188)W/(188)Re generator and status of current applications.
Pillai MR; Dash A; Knapp FF
Curr Radiopharm; 2012 Jul; 5(3):228-43. PubMed ID: 22642385
[TBL] [Abstract][Full Text] [Related]
16. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
[TBL] [Abstract][Full Text] [Related]
18. Preparation and evaluation of 186/188Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site.
Ogawa K; Kawashima H; Kinuya S; Shiba K; Onoguchi M; Kimura H; Hashimoto K; Odani A; Saji H
Ann Nucl Med; 2009 Dec; 23(10):843-8. PubMed ID: 19921351
[TBL] [Abstract][Full Text] [Related]
19. 188Re-direct labeling of monoclonal antibodies for radioimmunotherapy of solid tumors: biodistribution, normal organ dosimetry, and toxicology.
Iznaga-Escobar N
Nucl Med Biol; 1998 Jul; 25(5):441-7. PubMed ID: 9720661
[TBL] [Abstract][Full Text] [Related]
20. Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Schneider S; Strumpf A; Schetelig J; Wunderlich G; Ehninger G; Kotzerke J; Bornhäuser M
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1754-60. PubMed ID: 26001695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
